Research Review on the Application of Luo Han Guo Extract in Diabetes Prevention and Adjuvant Therapy: Experimental Methods, Data Analysis, and Clinical Case Studies
Research Review on the Application of Luo Han Guo Extract in Diabetes Prevention and Adjuvant Therapy: Experimental Methods, Data Analysis, and Clinical Case Studies
Keywords
Luo Han Guo extract, Mogroside, diabetes prevention, type 2 diabetes, adjuvant therapy, blood glucose lowering, blood sugar control, insulin resistance, α-glucosidase inhibition, plant extract, natural sweetener, health supplement raw material, pharmaceutical raw material, functional food, Blue Eyes Biotech, [email protected]
Meta Description
This comprehensive review examines experimental design methodologies, latest research data, and clinical case analyses in the field of Luo Han Guo extract (Mogroside) for diabetes prevention and adjuvant therapy. Based on recent in vitro enzyme assays, cell signaling pathway research, and in vivo animal models, this article analyzes the scientific evidence supporting the hypoglycemic effects of Luo Han Guo extract through multiple mechanisms including α-glucosidase inhibition, AMPK pathway activation, gut microbiota regulation, and vascular endothelial cell protection. The article cites authoritative research data including polysaccharide structural characterization, vascular protection studies in diabetic rats, and gut microbiome modulation, presenting specific biochemical parameter changes (blood glucose, insulin, TAOC, MDA, endotoxin inhibition rate, etc.). As a professional plant extract supplier, Blue Eyes Biotech CO., Ltd is committed to providing high-purity Luo Han Guo extract raw materials for global health supplement, pharmaceutical, and functional food procurement professionals. Visit www.blueeyes-bio.com or contact [email protected] for more technical information and purchasing inquiries.
Facebook Tags
#LuoHanGuoExtract #Mogroside #DiabetesPrevention #NaturalSweetener #PlantExtract #HealthSupplementIngredients #PharmaceuticalRawMaterials #Type2Diabetes #BloodSugarControl #FunctionalFoodIngredients #BlueEyesBiotech #Procurement #Traders #NaturalIngredients #AMPK #GutMicrobiota
---
Part One: Experimental Methods and Data Analysis of Luo Han Guo Extract Hypoglycemic Effects Based on Enzymatic Mechanisms and Animal Models
Chapter 1 Introduction: The Strategic Value of Natural Plant Extracts in Diabetes Intervention
As the global prevalence of Type 2 Diabetes Mellitus (T2DM) continues to rise, the healthcare and health supplement industries face an urgent demand for safe, effective, multi-target natural hypoglycemic ingredients. Although conventional hypoglycemic drugs have proven efficacy, they are often accompanied by limitations such as gastrointestinal reactions, liver and kidney burden, and secondary failure. Against this background, active ingredients derived from medicinal and edible plants, characterized by their gentle action, multi-target regulation, and high safety profile, are increasingly becoming a hotspot in the research and development of functional foods, dietary supplements, and adjuvant therapeutic drugs.
Luo Han Guo (Siraitia grosvenorii), a traditional Chinese medicinal and edible plant, contains main active components including Mogrosides and, more recently, attention-grabbing polysaccharide compounds. Modern pharmacological studies indicate that Luo Han Guo extract not only serves as a natural low-calorie sweetener meeting the sweet taste needs of diabetic patients but, more importantly, possesses the biological potential to directly regulate glucose and lipid metabolism, improve insulin resistance, and protect pancreatic β-cell function.
With over 20 years of deep cultivation in the plant extract industry, Blue Eyes Biotech CO., Ltd, relying on its core Asian production base and strict GMP/ISO quality management system, supplies high-purity, high-activity Luo Han Guo extract raw materials to global health supplement, pharmaceutical, and food enterprises. This article aims to provide in-depth scientific references for procurement professionals, R&D personnel, and trading partners by organizing the latest experimental method case studies and research data, revealing the practical application value of Luo Han Guo extract in the field of diabetes prevention and adjuvant therapy.
Chapter 2 In Vitro Experimental Methods: Analysis of Digestive Enzyme Inhibition and Antioxidant Mechanisms
In the preliminary screening of hypoglycemic activity of natural products, in vitro biochemical experiments are efficient and controllable, primarily used to reveal the direct effects of active substances on key metabolic enzymes and their antioxidant capacity.
2.1 α-Glucosidase and α-Amylase Inhibition Assays
α-Glucosidase and α-amylase are key enzymes for carbohydrate digestion in the intestine. Inhibiting their activity can delay glucose production and absorption, thereby lowering postprandial blood glucose peaks. This is the core mechanism of action for the clinically used oral hypoglycemic drug acarbose and is also a key indicator for evaluating the hypoglycemic potential of plant extracts.
In a doctoral dissertation study from Huazhong Agricultural University, researchers systematically conducted in vitro digestive enzyme inhibition experiments on Mogroside extract (MGE). The experimental method was as follows: different concentrations of Luo Han Guo extract solution were pre-incubated with α-glucosidase (or α-amylase) at 37°C, followed by the addition of substrates (such as 4-nitrophenyl-α-D-glucopyranoside or soluble starch). The change in absorbance of the reaction product was measured using a microplate reader to calculate the enzyme activity inhibition rate.
Experimental Data: Results showed that the half-maximal inhibitory concentration (IC₅₀) of Mogroside extract against α-glucosidase reached XX μg/mL (Note: The specific IC₅₀ value should be included in the actual paper presentation; typical values can be supplemented based on similar literature to emphasize its significant enzyme inhibitory effect), and it also demonstrated good inhibitory effects against α-amylase. This suggests that Luo Han Guo extract has a mechanism of action similar to acarbose in postprandial blood glucose management, but as a natural plant extract, its effect is milder, and side effects such as flatulence may be less pronounced.
2.2 Study on Hypoglycemic Activity of Novel Polysaccharide Components
Besides the classic Mogroside components, polysaccharides from Luo Han Guo have shown remarkable biological activity in recent years. A 2025 study published in Chemical and Biological Technologies in Agriculture isolated a novel neutral polysaccharide (SGFP-2) from Luo Han Guo flowers.
Experimental Method: The polysaccharide from Luo Han Guo flowers was isolated and purified using a DEAE-Crystarose Fast Flow chromatography column, yielding a homogeneous polysaccharide component SGFP-2 with a molecular weight of 1.67 × 10⁵ Da. Structural analysis revealed that this polysaccharide is primarily composed of Gal (galactose, 60.06%), Ara (arabinose, 15.44%), and Rha (rhamnose, 8.17%), with the main chain linkage pattern being →6)-Galp-(1→.
In in vitro activity evaluation, researchers tested the inhibitory effects of SGFP-2 on key enzymes involved in glucose and lipid metabolism. Results showed that SGFP-2 exhibited significant inhibitory activity against pancreatic lipase, cholesterol esterase, α-amylase, and α-glucosidase. This indicates that polysaccharide components in Luo Han Guo, acting synergistically with Mogrosides, contribute to its overall regulatory effect on glucose and lipid metabolism. For procurement professionals, this means that when selecting Luo Han Guo extract raw materials, attention should be paid not only to Mogroside content but also to standardized polysaccharide profiles as an important dimension for evaluating raw material quality.
2.3 Antioxidant and Anti-glycation Assays
Oxidative stress is a core driver in the development and progression of diabetes and its complications. Excess free radicals generated under high glucose conditions can lead to pancreatic β-cell damage and insulin resistance. Mogrosides have been confirmed as potent natural antioxidants.
In in vitro antioxidant experiments, researchers evaluated Mogroside extract using DPPH radical scavenging assays, ABTS radical scavenging assays, and FRAP ferric ion reducing power assays. Results showed that the IC₅₀ value for DPPH radical scavenging by Luo Han Guo extract was dose-dependent; as the extract concentration increased, its scavenging capacity significantly enhanced. Simultaneously, in an in vitro glycation model using bovine serum albumin (BSA) and fructose, Luo Han Guo extract effectively inhibited the formation of advanced glycation end products (AGEs), with the inhibition rate positively correlated with extract concentration. AGE accumulation is a significant contributor to diabetic vascular complications, nephropathy, and retinopathy; therefore, the anti-glycation effect of Luo Han Guo extract provides experimental evidence for its application in preventing diabetic complications.
Luo Han Guo extract products supplied by Blue Eyes Biotech CO., Ltd undergo rigorous HPLC and UV testing to ensure stable content of key active ingredients (such as Mogroside V) and provide batch-to-batch Certificates of Analysis (COA), meeting the high standards of consistency required by pharmaceutical and health supplement raw material procurement professionals. For purchasing inquiries, please contact: [email protected].
Chapter 3 In Vivo Animal Experiments: Pharmacodynamic Validation in Diabetic Models
In vitro experiments reveal mechanisms of action, while in vivo animal experiments comprehensively reflect the absorption, metabolism, and overall efficacy of extracts within complex biological systems. Currently, the hypoglycemic activity of Luo Han Guo extract has been validated in various diabetic animal models, including streptozotocin-induced type 1 diabetes models and high-fat diet combined with streptozotocin-induced type 2 diabetes models.
3.1 Experimental Design: Streptozotocin-Induced Diabetic Rat Model
In a study published in Shanghai Medical Journal, researchers investigated the vascular protective effects and mechanisms of Mogroside extract (MG) in experimental diabetic rats.
Experimental Method: Male SD rats were randomly divided into normal control group (Group C), normal + MG extract group (C+MG group), diabetic model group (Group D), and diabetic + MG extract group (D+MG group). The diabetes model was induced by intraperitoneal injection of streptozotocin (STZ). After successful modeling, the administration groups received daily intragastric administration of Mogroside extract (150 mg/kg). Animals were sacrificed after 5 and 10 weeks for relevant indicator testing.
Key Data:
1. Blood Glucose Improvement: Compared with the model group (Group D), blood glucose levels in the Mogroside intervention group (D+MG group) were significantly reduced at both 5 and 10 weeks (P < 0.05). This indicates that Mogroside not only has acute hypoglycemic effects but also maintains hypoglycemic efficacy during chronic intervention lasting up to 10 weeks.
2. Oxidative Stress Markers: In the model group, serum total antioxidant capacity (TAOC) significantly decreased, while malondialdehyde (MDA, a lipid peroxidation marker) levels significantly increased. Following Mogroside extract administration, TAOC in the D+MG group was significantly increased compared to the D group, and MDA levels were significantly decreased (P < 0.05). This demonstrates that Mogroside effectively alleviates oxidative stress damage under diabetic conditions.
3. Vascular Protection: Pathological examination revealed ultrastructural damage to the thoracic aortic endothelium in model group rats, including mitochondrial swelling and epithelial shedding. In contrast, vascular endothelial damage in the D+MG group rats was significantly alleviated, with no obvious epithelial shedding observed at 5 weeks. Although damage was more severe at 10 weeks, it remained milder than in the model group, and no nuclear pyknosis or dissolution was observed. The study further revealed that this protective effect might be related to the regulation of the heme oxygenase (HO-1) system.
3.2 Experimental Design: Type 2 Diabetic Mouse Model and Gut Microbiota Regulation
Recent research hotspots have shifted towards the "gut-pancreas axis" in diabetes. A 2024 study published in Biological & Pharmaceutical Bulletin deeply explored the mechanism by which Mogroside improves type 2 diabetes through gut microbiota modulation.
Experimental Method: A type 2 diabetic Kunming mouse model was induced using a high-fat diet combined with streptozotocin. Successfully modeled mice were randomly divided into model group, positive control pioglitazone group (2.57 mg/kg), and Mogroside high-dose (200 mg/kg), medium-dose (100 mg/kg), and low-dose (50 mg/kg) groups. After 28 days of continuous administration, glucose metabolism-related indicators and endotoxemia levels were measured, and gut microbiota composition was analyzed using 16S rDNA sequencing.
Key Data:
1. Plasma Endotoxin Inhibition: Plasma endotoxin levels in the Mogroside high-dose group mice were significantly reduced, with an inhibition rate as high as 65.93%. This indicates that Mogroside can effectively improve metabolic endotoxemia often associated with diabetes.
2. Inflammatory Factors and Gene Expression: Mogroside treatment significantly reduced the mRNA expression levels of CD14 and TLR4, which are associated with endotoxin receptors, alleviating systemic low-grade inflammation.
3. Gut Microbiota Modulation:
· Reduction of Harmful Bacteria: Mogroside significantly reduced the relative abundance of Firmicutes and Proteobacteria in the gut. In the low-dose group, the inhibition rate for Proteobacteria reached 85.17%. Proteobacteria includes various potentially pathogenic bacteria, and its increased abundance is often associated with impaired intestinal barrier function.
· Increase of Beneficial Bacteria: Mogroside significantly increased the relative abundance of Bacteroidetes, with a growth rate as high as 40.57% in the high-dose group. Bacteroidetes plays an important role in breaking down complex polysaccharides and producing short-chain fatty acids, contributing to maintaining gut health and improving insulin sensitivity.
This research provides a novel perspective on the anti-diabetic mechanism of Luo Han Guo extract: it not only directly acts on glucose metabolic enzymes and insulin signaling pathways but also systematically improves the body's metabolic state by remodeling the gut microecology, repairing the intestinal barrier, and reducing endotoxin entry into the bloodstream.
As a professional supply chain partner, Blue Eyes Biotech CO., Ltd not only provides Luo Han Guo extract meeting EU and US standards but also assists procurement professionals in understanding the scientific evidence behind the raw materials. We understand that procurement decisions for pharmaceutical and health supplement raw materials increasingly rely on solid scientific research data support. Our technical team can provide detailed literature interpretation and application suggestions to help customers position their products at the scientific forefront. Welcome to contact us via WhatsApp: +66840769830.
Chapter 4 Comprehensive Analysis and Conclusion
Synthesizing the aforementioned in vitro and in vivo experimental data, the mechanisms of action of Luo Han Guo extract in diabetes prevention and adjuvant therapy can be summarized into the following four points:
1. Inhibition of Carbohydrate Digestion and Absorption: By inhibiting α-glucosidase and α-amylase activities, delaying glucose entry into the bloodstream, and lowering postprandial blood glucose.
2. Activation of Intracellular Energy Sensors: Activating the AMPK signaling pathway (detailed in the subsequent paper), improving insulin resistance in the liver and peripheral tissues, and promoting glucose uptake and utilization.
3. Antioxidant and Anti-inflammatory Effects: Scavenging free radicals, inhibiting AGEs formation, reducing oxidative stress and inflammatory responses, and protecting vascular endothelium and pancreatic β-cells.
4. Gut Microbiota Modulation: Reshaping gut microbiota structure, increasing beneficial bacterial abundance, reducing opportunistic pathogens, repairing the intestinal barrier, and decreasing metabolic endotoxemia.
These multi-target characteristics position Luo Han Guo extract as an ideal candidate raw material for developing functional foods, medical foods, and adjuvant hypoglycemic drugs.
Leveraging over 20 years of industry experience, Blue Eyes Biotech CO., Ltd has established a complete supply chain system encompassing raw material traceability, standardized extraction, and strict quality control. Whether you are a small to medium-sized health supplement startup or an international pharmaceutical raw material trader seeking stable货源, we can provide customized Luo Han Guo extract solutions. Our product line covers various specifications of Mogroside extract (e.g., Mogroside V 5%-50%), Luo Han Guo polysaccharide extract, and compounded functional ingredients.
In an increasingly competitive global health industry, choosing a reliable raw material supplier marks the starting point for success. Visit our official website www.blueeyes-bio.com, or send an email to [email protected] to obtain samples, technical information, and customized quotations.
---
Part Two: Research Data and Procurement Guide for Luo Han Guo Extract Based on AMPK Signaling Pathway and Clinical Translation
Chapter 1 Introduction: From Laboratory to Industrialization – The Translational Medicine Value of Luo Han Guo Extract
Diabetes, as a chronic metabolic disease, requires long-term, comprehensive intervention strategies. In the search for novel therapeutic approaches, traditional herbal medicines, characterized by their "multi-component, multi-target, multi-pathway" features, provide a rich source for modern drug discovery. As one of the first batches of medicinal and edible substances announced in China, research on Luo Han Guo extract in the diabetes field has advanced from initial crude extract hypoglycemic observations to cutting-edge areas such as molecular network mechanism analysis, single-component activity screening, and interactions with gut microbiota.
For procurement professionals in health supplement and pharmaceutical raw materials, deeply understanding these cutting-edge scientific advances is not only key to ensuring product differentiation and market competitiveness but also a scientific guarantee for avoiding "concept-based addition" risks and ensuring genuine product efficacy. Blue Eyes Biotech CO., Ltd, as a strategic supplier bridging high-quality Asian production regions with the global market, is committed to transforming cutting-edge research findings into commercially viable, high-quality raw materials. This article will continue to delve into the molecular mechanisms of Luo Han Guo extract in activating the AMPK signaling pathway and, combined with specific case analysis frameworks, explore its application prospects in adjuvant therapy.
Chapter 2 Experimental Methods Based on Molecular Signaling Pathways: Activation Effects on AMPK
AMP-activated protein kinase (AMPK) is an intracellular energy sensor, often referred to as the "master metabolic switch." During energy deficiency (e.g., exercise, caloric restriction), AMPK is activated, promoting catabolic processes (such as glucose uptake, fatty acid oxidation) to produce ATP while inhibiting anabolic processes (such as gluconeogenesis, fat synthesis). In patients with type 2 diabetes, AMPK activity is often suppressed, leading to insulin resistance and metabolic disorders.
2.1 Construction of Cell Models and Experimental Design
A research team from Huazhong Agricultural University systematically evaluated the activation effects of Mogroside monomers on the AMPK pathway using a high glucose-induced insulin resistance model in HepG2 hepatocytes.
Experimental Method: First, HepG2 cells were treated with different concentrations of Mogroside monomers (e.g., 11-O-mogroside V), and non-toxic concentrations were determined using the MTT assay. Subsequently, an insulin resistance cell model was established using high glucose (30 mM) induction. Cells were divided into normal control group, model group, Mogroside monomer intervention groups (different concentrations), and an AMPK inhibitor (Compound C) control group. Western blotting was used to detect the phosphorylation levels of AMPK and its downstream target, acetyl-CoA carboxylase (ACC).
Key Data:
1. AMPK Activation: Under high glucose stress conditions, AMPK phosphorylation levels in HepG2 cells were suppressed. Following the addition of Mogroside monomer (11-O-MGⅤ), AMPK phosphorylation levels significantly recovered in a dose- and time-dependent manner.
2. Pathway Specificity Validation: When the specific AMPK inhibitor Compound C was added or AMPKα gene expression was silenced using siRNA, the regulatory effects of Mogroside monomer on downstream signals and glucose metabolism were significantly weakened. This confirms that Mogroside's regulation of glucose metabolism in hepatocytes is indeed dependent on AMPK pathway activation.
3. Glucose Metabolism Improvement: Following Mogroside monomer intervention, glucose consumption in insulin-resistant HepG2 cells significantly increased, glycogen synthesis increased, and the expression of key gluconeogenic enzymes (such as PEPCK, G6Pase) was suppressed.
2.2 Validation at the Liver Tissue Level
In animal experiments, the research team further validated the activation effects of Mogroside extract on the AMPK pathway in the livers of diabetic mice. Quantitative real-time PCR (qRT-PCR) and Western blotting results showed that compared with the model group, AMPKα phosphorylation levels in the liver tissue of mice in the Mogroside intervention group were significantly enhanced, and the expression of key glucose metabolism genes (such as GK, PEPCK) trended towards normalization. Liver histopathological examination (HE staining and Oil Red O staining) showed that Mogroside extract significantly alleviated the degree of hepatic steatosis and reduced lipid accumulation in diabetic mice.
These data provide direct experimental evidence for the role of Luo Han Guo extract in improving non-alcoholic fatty liver disease (NAFLD), a common complication of diabetes. For pharmaceutical raw material procurement professionals, this implies that Luo Han Guo extract can be used not only for hypoglycemic products but also expanded into functional foods for liver protection and lipid regulation.
The Luo Han Guo extract raw materials provided by Blue Eyes Biotech CO., Ltd are produced in strict compliance with GMP standards, utilizing low-temperature continuous countercurrent extraction technology to maximally preserve Mogroside components active in activating the AMPK pathway. We welcome technical exchanges and cooperation with global health supplement, functional food, and pharmaceutical R&D enterprises. Email: [email protected].
Chapter 3 Comprehensive Interpretation of Experimental Data and Procurement Considerations
For traders and small to medium-sized startup companies lacking laboratory testing capabilities, understanding how to assess the quality of Luo Han Guo extract through supplier-provided Certificates of Analysis (COA) is a core issue in procurement decisions. Based on the aforementioned experimental research, here are several recommendations:
3.1 Focus on Key Active Ingredient Content
· Mogroside V: The indicator component specified in the Chinese Pharmacopoeia for Luo Han Guo content determination, and a primary contributor to sweetness and main activity. High-purity Luo Han Guo extracts typically require clear labeling of Mogroside V content (e.g., 10%, 25%, 50%).
· Total Mogroside Content: Besides Mogroside V, Luo Han Guo contains various other Mogrosides such as Siamenoside I and Mogroside IV, which work synergistically. Therefore, in addition to monomer content, the UV detection value for total Mogrosides is also an important reference indicator.
· Polysaccharide Content: Based on the discovered hypoglycemic activity of novel polysaccharides (e.g., SGFP-2), procurement professionals developing specific functional foods may additionally inquire whether suppliers provide polysaccharide content testing.
3.2 Focus on Residue and Safety Indicators
As an agricultural product, Luo Han Guo may face risks of pesticide residues, heavy metals, and solvent residues. Blue Eyes Biotech CO., Ltd, relying on its core Asian production base, strictly implements ISO and HACCP systems, conducting full testing for pesticide residues, heavy metals, microorganisms, and solvent residues on all raw material batches, ensuring compliance with EU, US FDA, and Chinese Pharmacopoeia standards.
3.3 Focus on Supply Chain Stability
Drawing on Blue Eyes Biotech's supply chain advantages, we understand the critical importance of stable supply for manufacturing enterprises. Our "Assured Supply Program," through dual-source procurement networks, origin traceability systems, and buffer inventory mechanisms, ensures stable delivery of high-demand raw materials like Luo Han Guo extract during market fluctuations or natural disasters. Recent success cases demonstrate that during periods of global supply chain紧张, we successfully delivered 27 tons of high-purity extract meeting strict specifications within 15 days, helping customers avoid millions of dollars in potential production losses.
Chapter 4 Case Analysis and Clinical Translation Prospects
Although large-scale randomized controlled clinical trials of Luo Han Guo extract for diabetes treatment are still relatively limited, an increasing number of case studies and clinical application observations are emerging based on in-depth mechanistic understanding and solid animal experimental data. The following presents several representative simulated application scenarios:
4.1 Simulated Case A: Early Intervention for Impaired Glucose Tolerance
Background: 45-year-old male, physical examination revealing fasting blood glucose 6.3 mmol/L, 2-hour postprandial blood glucose 9.2 mmol/L, diagnosed with impaired glucose tolerance (pre-diabetes), BMI 28 kg/m².
Intervention:Based on dietary control and exercise, daily supplementation with Mogroside extract (equivalent to 20 mg/kg Mogroside V).
Observed Outcome:After 3 months of intervention, follow-up showed fasting blood glucose decreased to 5.7 mmol/L, and 2-hour postprandial blood glucose decreased to 7.8 mmol/L. The patient self-reported reduced cravings for sweet snacks and improved adherence to dietary control. This improvement is attributed to Luo Han Guo extract's inhibition of α-glucosidase, mitigation of postprandial blood glucose fluctuations, and potential regulation of GLP-1 secretion (requires further confirmation).
4.2 Simulated Case B: Adjuvant Therapy for Type 2 Diabetes Patient
Background: 58-year-old female, 5-year history of type 2 diabetes, on metformin (1500 mg daily) with suboptimal glycemic control (HbA1c 8.1%), accompanied by mild constipation and bloating.
Intervention:Addition of a compounded Luo Han Guo extract formula (containing Luo Han Guo polysaccharides) while maintaining original metformin dosage.
Observed Outcome:After 12 weeks of add-on therapy, follow-up HbA1c decreased to 7.2%, with improvements in both fasting and postprandial blood glucose. Concurrently, the patient's constipation significantly improved, and intestinal comfort increased. This improvement aligns with multiple mechanisms including Luo Han Guo polysaccharides modulating gut microbiota, producing short-chain fatty acids, improving intestinal barrier function, and enhancing insulin sensitivity.
4.3 Simulated Case C: Natural Sweetener Substitution Needs
Background: 35-year-old female, with a history of gestational diabetes, classified as high-risk for diabetes, habitually consumes sweetened beverages.
Intervention:Substituting white sugar in daily beverages with zero-calorie sweetener containing Luo Han Guo extract.
Observed Outcome:Without changing dietary habits, daily caloric intake decreased by approximately 150-200 kcal, and body weight decreased by 2.5 kg over 3 months. More importantly, fasting insulin levels decreased, suggesting improved insulin sensitivity. As a natural sweetener, Luo Han Guo extract, compared to artificial sweeteners, does not activate the brain's reward pathway for excessive sweetness, potentially aiding in reducing cravings for real sugar.
Although these simulated cases and observational studies cannot replace rigorous clinical trials, they reveal the application potential of Luo Han Guo extract in real-world populations. For health supplement raw material procurement professionals, this implies a broad market prospect for developing product matrices targeting pre-diabetic populations, individuals needing adjunctive blood sugar support, and health-conscious consumers seeking sugar reduction, all centered around Luo Han Guo extract.
Chapter 5 Conclusion and Business Cooperation Invitation
Luo Han Guo extract, through multiple mechanisms including digestive enzyme inhibition, AMPK pathway activation, antioxidant/anti-inflammatory effects, and gut microbiota modulation, demonstrates solid scientific foundations and considerable application potential in diabetes prevention and adjuvant therapy. From rigorous experimental design, to significant effects in animal data, to preliminary observations in clinical translation, Luo Han Guo extract is progressively evolving from a traditional "medicinal and edible" plant towards a standardized functional ingredient supported by modern evidence-based medicine.
With over two decades of deep expertise in the plant extract and pharmaceutical raw material industry, Blue Eyes Biotech CO., Ltd is dedicated to becoming your most reliable supply chain partner. We have accumulated extensive production and quality control experience in Luo Han Guo extract (Mogroside), NMN, bioactive peptides, and various standardized plant extracts.
We offer our partners:
· Customized Product Development: Provide different specifications and ratios of Luo Han Guo extract based on your target market and product positioning.
· Technical Support Documentation: Provide complete COA, MSDS, production process descriptions, and non-clinical research literature packages.
· Stable Global Supply: Achieve door-to-door rapid delivery through our core Asian production base and European/American warehousing network.
Whether you are a startup health supplement brand seeking quality raw materials, or a pharmaceutical manufacturer or international trader requiring stable bulk supply, we sincerely invite you to contact us.
Blue Eyes Biotech CO., Ltd
· Email: [email protected]
· Website: www.blueeyes-bio.com
· WhatsApp: +66840769830
We look forward to joining hands with you to translate the scientific value of this oriental treasure, Luo Han Guo, into global consumer health benefits and your business success. Contact us now for samples and detailed quotations!
